BFLY
Bearish signalScored 2026-10-12 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Butterfly Network, Inc.
- Nom
- Butterfly Network, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $1.8B
- Employés
- 220
- PDG
- Joseph DeVivo
- Site web
- https://www.butterflynetwork.com
- Marché
- AMNARVNATXSDAWNEVHFLGT
Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks. Additionally, Butterfly Blueprint is offered as a comprehensive, system-wide ultrasound platform that seamlessly integrates its proprietary Compass software into a healthcare provider's clinical and administrative infrastructure. These ultrasound systems, encompassing probes, related accessories, and software subscriptions, are supplied to healthcare systems, individual physicians, and other medical professionals through a multi-channel distribution strategy that includes a direct sales force, a network of distributors, and an e-commerce platform. Beyond its hardware, Butterfly Network provides a suite of cloud-based software solutions for healthcare organizations. These offerings feature teleguidance services, interactive in-app educational modules, and structured training programs delivered via its Butterfly Academy software, all complemented by dedicated clinical support and services. Established in 2011, Butterfly Network, Inc. has its corporate headquarters situated in Guilford, Connecticut.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 41 770 titres (~418 482,35 $ US)
- Insiders
- DEVIVO JOSEPH
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,967,709
Avg sell (VWAP, 90d window) $8.37 vs last close $7.25 (-13.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,102,557 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-06
- Liquidity
- Liquid $43,609,179/day · 20d vol
- Last synced
-
2026-10-17 09:40:09
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | DEVIVO JOSEPH | Sell · S · 10b5-1 | 35,790 | $10.02 | $358,616 | Form 4 |
| 2026-10-02 | Carlson Megan | Sell · S | 10,114 | $8.74 | $88,447 | Form 4 |
| 2026-09-23 | DEVIVO JOSEPH | Sell · S · 10b5-1 | 3,169 | $10.02 | $31,757 | Form 4 |
| 2026-09-22 | DEVIVO JOSEPH | Sell · S · 10b5-1 | 2,811 | $10.00 | $28,110 | Form 4 |
| 2026-09-04 | Carlson Megan | Sell · S | 13,804 | $7.30 | $100,797 | Form 4 |
| 2026-09-04 | Cashman Steve | Sell · S | 140,112 | $7.30 | $1,023,098 | Form 4 |
| 2026-09-02 | Caezza Nicholas | Sell · S | 1,709 | $8.15 | $13,927 | Form 4 |
| 2026-08-11 | Caezza Nicholas | Sell · S | 10,000 | $9.75 | $97,500 | Form 4 |
| 2026-08-10 | DEVIVO JOSEPH | Sell · S · 10b5-1 | 68,346 | $10.01 | $684,075 | Form 4 |
| 2026-07-31 | Carlson Megan | Sell · S | 68,852 | $7.86 | $541,383 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-12 Drivers: fundamentals. Moteurs : fondamentaux.
BFLY presents a mixed profile: a meaningful catalyst in the Bridge Neurotech BCI partnership has driven shares to a 52-week high and aligns with a high-interest thematic trend, but the company's weak fundamentals —…
The first sentence of the analysis written for BFLY on 2026-10-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Unavailable or mixed. Current ratio 3.83 · operating margin -89% — readings disagree
Suggested stop 6.69, nearest stored support minus 0.5 ATR(7.7% under the last close). Reward/risk to the next stored resistance is 3.01. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 46.9% | 59.5% | 25.6% | 53.8% | 27.3% | |
| Ebit Margin | -77.3% | -86.8% | -202.8% | -229.8% | -50.6% | |
| Ebitda Margin | -69.0% | -74.2% | -186.7% | -221.8% | -47.2% | |
| Operating Profit Margin | -88.5% | -90.7% | -221.0% | -263.0% | -308.0% | |
| Pretax Profit Margin | -78.8% | -88.4% | -202.8% | -229.8% | -51.6% | |
| Continuous Operations Profit Margin | -79.0% | -88.3% | -202.9% | -229.9% | -51.8% | |
| Net Profit Margin | -79.0% | -88.3% | -202.9% | -229.9% | -51.8% | |
| Bottom Line Profit Margin | -79.0% | -88.3% | -202.9% | -229.9% | -51.8% | |
| Current Ratio | 3.825 | 3.995 | 5.224 | 6.958 | 10.273 | |
| Quick Ratio | 2.883 | 2.527 | 3.574 | 5.789 | 9.546 | |
| Solvency Ratio | -0.686 | -0.712 | -1.462 | -1.765 | -0.244 | |
| Cash Ratio | 2.311 | 1.841 | 3.041 | 3.167 | 8.486 | |
| Price To Earnings Ratio | -12.258 | -9.176 | -1.662 | -2.929 | -35.211 | |
| Price To Earnings Growth Ratio | 1.389 | 0.192 | 0.073 | -0.009 | 0.355 | |
| Forward Price To Earnings Growth Ratio | 1.389 | 0.192 | 0.073 | -0.009 | 0.355 | |
| Price To Earnings Diluted Ratio | -12.258 | -9.176 | -1.662 | -2.929 | -35.211 | |
| Price To Earnings Diluted Growth Ratio | 1.389 | 0.192 | 0.073 | -0.009 | 0.355 | |
| Price To Book Ratio | 4.792 | 3.912 | 1.008 | 1.511 | 2.597 | |
| Price To Sales Ratio | 9.621 | 8.049 | 3.366 | 6.699 | 18.585 | |
| Price To Free Cash Flow Ratio | -58.516 | -14.875 | -2.121 | -2.623 | -5.901 | |
| Price To Operating Cash Flow Ratio | -73.943 | -15.835 | -2.245 | -2.907 | -6.146 | |
| Debt To Assets Ratio | 0.069 | 0.089 | 0.082 | 0.076 | 0.051 | |
| Debt To Equity Ratio | 0.104 | 0.135 | 0.114 | 0.098 | 0.065 | |
| Debt To Capital Ratio | 0.094 | 0.119 | 0.102 | 0.089 | 0.061 | |
| Long Term Debt To Capital Ratio | 0.083 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.513 | 1.517 | 1.383 | 1.283 | 1.278 | |
| Working Capital Turnover Ratio | 0.594 | 0.495 | 0.267 | 0.191 | 0.256 | |
| Operating Cash Flow Ratio | -0.195 | -0.865 | -2.232 | -3.295 | -3.797 | |
| Operating Cash Flow Sales Ratio | -0.130 | -0.508 | -1.500 | -2.304 | -3.024 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.264 | 1.065 | 1.059 | 1.108 | 1.042 | |
| Debt Service Coverage Ratio | -45.297 | -16.465 | -56.171 | -84.433 | -14.529 | |
| Interest Coverage Ratio | -57.997 | -59.010 | 0.000 | -96,510.000 | -296.049 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -17.114 | -45.082 | -87.806 | -136.008 | |
| Operating Cash Flow Coverage Ratio | -0.623 | -1.826 | -3.949 | -5.303 | -6.506 | |
| Capital Expenditure Coverage Ratio | -3.793 | -15.481 | -17.088 | -9.240 | -24.018 | |
| Dividend Paid And Capex Coverage Ratio | -3.793 | -15.481 | -17.088 | -9.240 | -24.018 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.006 | -9.759 | -0.912 | -2.218 | -26.027 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 46.9% | ▼-12.7% | ▲4.3% |
| Ebit Margin | -77.3% | ▲9.5% | ▲52.1% |
| Ebitda Margin | -69.0% | ▲5.2% | ▲50.8% |
| Operating Profit Margin | -88.5% | ▲2.1% | ▲105.7% |
| Pretax Profit Margin | -78.8% | ▲9.6% | ▲51.4% |
| Continuous Operations Profit Margin | -79.0% | ▲9.4% | ▲51.4% |
| Net Profit Margin | -79.0% | ▲9.4% | ▲51.4% |
| Bottom Line Profit Margin | -79.0% | ▲9.4% | ▲51.4% |
| Current Ratio | 3.825 | ▼-0.169 | ▼-2.230 |
| Quick Ratio | 2.883 | ▲0.356 | ▼-1.981 |
| Solvency Ratio | -0.686 | ▲0.026 | ▲0.288 |
| Cash Ratio | 2.311 | ▲0.470 | ▼-1.458 |
| Price To Earnings Ratio | -12.258 | ▼-3.082 | ▼-0.011 |
| Price To Earnings Growth Ratio | 1.389 | ▲1.197 | ▲0.989 |
| Forward Price To Earnings Growth Ratio | 1.389 | ▲1.197 | ▲0.989 |
| Price To Earnings Diluted Ratio | -12.258 | ▼-3.082 | ▼-0.011 |
| Price To Earnings Diluted Growth Ratio | 1.389 | ▲1.197 | ▲0.989 |
| Price To Book Ratio | 4.792 | ▲0.880 | ▲2.028 |
| Price To Sales Ratio | 9.621 | ▲1.572 | ▲0.357 |
| Price To Free Cash Flow Ratio | -58.517 | ▼-43.642 | ▼-41.709 |
| Price To Operating Cash Flow Ratio | -73.943 | ▼-58.107 | ▼-53.727 |
| Debt To Assets Ratio | 0.069 | ▼-0.020 | ▼-0.005 |
| Debt To Equity Ratio | 0.104 | ▼-0.031 | ▲0.001 |
| Debt To Capital Ratio | 0.094 | ▼-0.025 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.083 | ▲0.083 | ▲0.066 |
| Financial Leverage Ratio | 1.513 | ▼-0.004 | ▲0.118 |
| Working Capital Turnover Ratio | 0.595 | ▲0.099 | ▲0.234 |
| Operating Cash Flow Ratio | -0.195 | ▲0.670 | ▲1.882 |
| Operating Cash Flow Sales Ratio | -0.130 | ▲0.378 | ▲1.363 |
| Free Cash Flow Operating Cash Flow Ratio | 1.264 | ▲0.199 | ▲0.156 |
| Debt Service Coverage Ratio | -45.297 | ▼-28.832 | ▼-1.918 |
| Interest Coverage Ratio | -57.997 | ▲1.013 | ▲19326.614 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲17.114 | ▲57.202 |
| Operating Cash Flow Coverage Ratio | -0.623 | ▲1.204 | ▲3.019 |
| Capital Expenditure Coverage Ratio | -3.793 | ▲11.688 | ▲10.131 |
| Dividend Paid And Capex Coverage Ratio | -3.793 | ▲11.688 | ▲10.131 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.006 | ▼-2.247 | ▼-1.821 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $939.1M | $660.5M | $221.8M | $491.6M | $1.16B | |
| Enterprise value | $809.0M | $594.5M | $112.2M | $361.0M | $769.0M | |
| EV / Sales | 8.29x | 7.25x | 1.70x | 4.92x | 12.29x | |
| EV / Op. cash flow | -63.70x | -14.25x | -1.14x | -2.13x | -4.07x | |
| EV / Free cash flow | -50.41x | -13.39x | -1.07x | -1.93x | -3.90x | |
| EV / EBITDA | -12.01x | -9.76x | -0.91x | -2.22x | -26.03x | |
| Net debt / EBITDA | 1.93x | 1.08x | 0.89x | 0.80x | 13.33x | |
| Current ratio | 3.83x | 4.00x | 5.22x | 6.96x | 10.27x | |
| Income quality | 0.17x | 0.57x | 0.74x | 1.00x | 5.84x | |
| Graham net-net | $0 | $0 | $0 | $1 | $2 | |
| Tax burden | 100.1% | 100.0% | 100.1% | 100.0% | 100.4% | |
| Interest burden | 102.0% | 101.8% | 100.0% | 100.0% | 102.1% | |
| Working capital | $184.0M | $144.4M | $187.0M | $305.8M | $462.1M | |
| Invested capital | $220.7M | $187.1M | $238.3M | $358.7M | $500.9M | |
| Return on assets | -26.0% | -28.3% | -43.9% | -40.4% | -5.7% | |
| Operating ROA | -31.3% | -26.6% | -40.3% | -39.0% | -53.6% | |
| Return on tangible assets | -26.7% | -29.3% | -45.5% | -40.4% | -5.7% | |
| Return on equity | -39.3% | -42.9% | -60.8% | -51.9% | -7.2% | |
| Return on invested capital | -36.9% | -35.4% | -55.5% | -52.4% | -36.8% | |
| Return on capital employed | -37.3% | -35.8% | -56.0% | -52.7% | -36.9% | |
| Earnings yield | -8.2% | -11.0% | -60.3% | -34.3% | -2.8% | |
| Free cash flow yield | -1.7% | -6.7% | -47.2% | -38.1% | -16.9% | |
| Capex / Op. cash flow | -26.4% | -6.5% | -5.9% | -10.8% | -4.2% | |
| Capex / Depreciation | 41.4% | 26.0% | 54.7% | 308.4% | 376.9% | |
| Capex / Sales | 3.4% | 3.3% | 8.8% | 24.9% | 12.6% | |
| SG&A / Sales | 87.2% | 104.1% | 162.1% | 196.8% | 216.3% | |
| R&D / Sales | 37.1% | 46.1% | 84.4% | 120.0% | 119.0% | |
| Stock comp / Sales | 24.0% | 25.6% | 41.7% | 58.0% | 76.4% | |
| Intangibles / Total assets | 2.5% | 3.5% | 3.4% | 0.0% | 0.0% | |
| Days sales outstanding | 100d | 92d | 74d | 73d | 70d | |
| Days payables outstanding | 38d | 47d | 38d | 78d | 46d | |
| Operating cycle | 532d | 870d | 618d | 718d | 360d | |
| Cash conversion cycle | 494d | 823d | 580d | 641d | 314d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-11 Butterfly Network (NYSE:BFLY) Shares Up 6.6% – Here’s What Happened Butterfly Network, Inc. (NYSE: BFLY - Get Free Report)''s stock price was up 6.6% on Friday. The company traded as high as $8.64 and last traded at $8.5560. Approximately 821,958 shares were traded during mid-day trading, a decline of 87% from the average session volume of 6,461,176 shares. The stock had previously closed at $8.03. Analysts
- 2026-10-09 Beyond Elon Musk''s Neuralink: Two Public Stocks With a Stake in the Brain Race Elon Musk''s Neuralink is giving us a glimpse of a future in which the human brain can communicate directly with computers. For investors, there''s just one problem: You can''t buy Neuralink stock.
- 2026-10-08 Butterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026 BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcas.
- 2026-10-07 Butterfly Network Lands Multi-Year Bridge Neurotech Deal Butterfly Network Inc. (NYSE:BFLY) is partnering with Bridge Neurotech to develop a fully non-invasive brain-computer interface using ultrasound technology.
- 2026-10-06 Bridge Neurotech and Butterfly Network Announce Partnership to Develop Fully Non-Invasive Brain-Computer Interface BURLINGTON, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $BFLY #BCI--Bridge Neurotech ("Bridge"), which emerged from stealth today with the goal of building a completely non-invasive brain-computer interface (BCI), and Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound, programmable cloud software and AI, today announced a research and development agreement through Butterfly Embedded™. Bridge was founded with a mission to make BCIs possible without.
- 2026-10-06 Butterfly Network (NYSE:BFLY) Sets New 12-Month High – Should You Buy? Butterfly Network, Inc. (NYSE: BFLY - Get Free Report)''s stock price reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $10.21 and last traded at $9.38, with a volume of 1041894 shares trading hands. The stock had previously closed at $9.38. Wall Street Analyst Weigh In A number of
- 2026-10-06 Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY) Zimmer Biomet (NYSE: ZBH - Get Free Report) and Butterfly Network (NYSE: BFLY - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Analyst Ratings This is a summary of recent
- 2026-10-05 Butterfly Network Appoints Mike Noonen to Board of Directors NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Mike Noonen to its Board of Directors, effective October 9, 2026. Mr. Noonen will serve on the Board''s Compensation Committee and Technology Committee. With his appointment, the Board expands to seven directors. Mr. Noonen is a seasoned semiconductor executive with.
- 2026-10-02 Neuralink Stock: How to Invest Before the IPO You can''t buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
- 2026-10-01 Mendaera''s Focalist™ System Now Compatible with Butterfly''s Ultrasound-on-Chip™ Technology BURLINGTON, Mass. & SAN MATEO, Calif.--(BUSINESS WIRE)---- $BFLY #POCUS--Mendaera, Inc., a healthcare technology company building robotics and intelligence for procedural medicine, and Butterfly Network, Inc. (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound, programmable cloud software and AI, today announced that Mendaera''s Focalist™ system is now commercially available with Butterfly Network''s Ultrasound-on-Chip™ imaging technology. Mendaera''s FDA-cleared Focalist system combines handheld.